Aug. 12, 2025 -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has commenced purchases of Ethereum (ETH), advancing its digital asset treasury reserve strategy. Pursuant to its financing facility of up to $300 million (the “Facility”) with a U.S.-based institutional investor, Cosmos Health has completed its initial $1 million purchase of ETH. Greg Siokas, CEO of Cosmos Health, stated:

Aug. 07, 2025 -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu thereof, with each pre-funded unit cons

$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand $55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and Ligand Proceeds extend expected cash runway into the second half of 2027 and expected to fund completion of enrollment and follow up for the primary endpoint of the BACKBEAT study, as well as substantial enrollment of the Virtue Trial Aug. 05, 2025 -- Orchestra Bi

• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease • Agreement links the organizations’ next-generation proteomics technology and neuroscience leadership to potentially unlock breakthrough therapeutics and biomarkers for neurodegenerative disease July 30, 2025 -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering single-molecule proteome analysis, today

Galway, London, 29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026. The €12 million grant, the larges

July 25, 2025 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up to approximately $100 million. The initial closing of approximately $50 million of common stock at a price of $13.32 per share is anticipated to occur on or abo

July 24, 2025 -- TCG Labs Soleil, a venture firm integrating dedicated capital with an in-house biotech R&D hub, today announced that it has raised an additional $400 million. This new funding builds on the firm’s inaugural raise of $400 million in 2024, expanding its ability to efficiently advance single-asset portfolio companies through clinical proof of concept and position them for strategic partnerships. With a fully integrated structure, TCG Labs Soleil retains full authority over asset

Financing led by Suvretta Capital Management and SR One with participation from 16 additional healthcare investors Proceeds will support key clinical milestones across all of Avalyn’s pipeline programs July 22, 2025 -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced the closing of an oversubscribed $100 million Series D financing. The raise was co-led by Suv

July 17, 2025 -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced it has received $1.9 million in non-dilutive funding to support its ongoing research and development programs. The funding will specifically accelerate the clinical development of urcosimod,

-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Multiple hotspot Prime Editors may benefit more than 93% of people with CF -- July 16, 2025 -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced t